- Trial phase
- Approved (marketed); additional Phase 3 programs completed/terminated
- Time to market
- Already marketed, approved in the US since January 2015; label-expansion filings for PMR/GCA are possible but no submission or decision date is recorded.
- Why 4/10
- No hard, dated binary in the next ~12 months: Cosentyx is already approved (original FDA approval Jan 2015) and its remaining Phase 3 expansion programs (polymyalgia rheumatica, giant cell arteritis) are completed with results not yet posted, submissions would be news but no PDUFA/readout date is scheduled, and the drug is one of many products at a mega-cap, so impact caps at 4.
Watch for Novartis disclosures on the completed PMR (381 patients, primary completion Sept 2025) and GCA (354 patients) Phase 3 programs, a regulatory submission for either would be the next meaningful Cosentyx catalyst, though it would move a ~$156 mega-cap modestly. Also track IL-17 competition and any biosimilar entry, plus the next quarterly 6-K for Cosentyx sales trajectory.
Price Chart
Executive Summary
Cosentyx (secukinumab) is Novartis's (NVS, US-listed) long-approved IL-17A-blocking biologic, a top-selling immunology franchise first cleared by the FDA in January 2015, with subsequent label actions including an Oct 2023 approval catalyst and a March 2025 supplemental approval for the IV formulation. As an already-marketed blockbuster with no scheduled PDUFA or pivotal readout date on the calendar, the drug itself is a stable cash-flow asset rather than a binary catalyst, though two large Phase 3 expansion studies (PMR, 381 patients; GCA, 354 patients) completed in early 2026 with results still unpublished, a potential future label expansion.
How It Works
Cosentyx (secukinumab) is an injected biologic (monoclonal antibody) that targets and neutralizes a specific immune messenger, IL-17A, that drives inflammation in skin and joint diseases such as psoriasis, psoriatic arthritis and ankylosing spondylitis, and which Novartis has been testing in other inflammatory conditions like giant cell arteritis and polymyalgia rheumatica. Blocking that messenger dampens the inflammatory attack.
Trial Status
FDA action records show the original approval (2015-01-21), an approval catalyst in Oct 2023, and a supplemental labeling approval for the IV injectable form (2025-03-12). Novartis Phase 3 trials in polymyalgia rheumatica (NCT05767034, 381 enrolled, completed Feb 2026) and giant cell arteritis (NCT04930094, 354 enrolled, completed Feb 2026; plus a 151-patient GCA-remission study) are COMPLETED with results not yet posted; a Chinese nr-axSpA Phase 3 (137 patients) completed; the thyroid eye disease (28 patients) and rotator cuff tendinopathy (33 patients) Phase 3 studies were TERMINATED.
The Two-Sided Case
Upcoming Catalysts
- Publication/presentation of results from the completed Phase 3 PMR (NCT05767034) and GCA (NCT04930094) studies, and any resulting regulatory submissions
- Next quarterly results (6-K filings) with Cosentyx sales trajectory
- Any label/regulatory actions for new indications or competitor/biosimilar entries in IL-17 space
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report